Top Stories

The National Lipid Association (NLA) has named Matthew Ito, PharmD (’86), as its new president. Membership of the NLA includes physicians, pharmacists, researchers, nurses, physician assistants and dietitians.

USC School of Pharmacy News – June 2013

On Friday, May 3, the U.S. FDA approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. For more information, please click here to read the announcement by Merck & Co.

On April 23, Amarin Corp. issued a press release announcing that the U.S. FDA has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG =200 mg/dL and < 500 mg/dL) with mixed dyslipidemia.

The FDA's review of Vascepa is expected to be completed by December 20, 2013.